Developer docsAPI playgroundTry for free, no card
Developer docs↗API playgroundTry for free, no cardConnect your agent to akta.pro and build company lists like this across sectors and geos.
The top 25 vertical AI healthcare companies in the US, any stage: privately held, US-headquartered, ranked by total capital raised, with most recent round, offering and revenue model for each. Data compiled .
| Company | Category | Most Recent Round | Total Funding | Offering | Management | Revenue Model |
|---|---|---|---|---|---|---|
| Altos Labs 🇺🇸 San Francisco, CA | AI/ML-Enabled Biologic Discovery (Cellular Rejuvenation) | Series A Sep 2021 | Funding $3.00B | AI/ML-native cellular rejuvenation platform using partial epigenetic reprogramming (Yamanaka factors) to reverse age-related cellular disease, run through an Institute of Computation integrating AI/ML with experimental biology. | Hal Barron CEO, Founder and Board Co-Chair Hans Bishop President, Founder and Board Co-Chair Kevin Sin Chief Financial and Business Officer | Licensing Royalties |
| Xaira Therapeutics 🇺🇸 South San Francisco, CA | AI/ML Drug Discovery Platform | Series A Apr 2024 | Funding $1.00B | AI-native biotechnology company building foundation models (X-Cell virtual cell model, Perturb-seq datasets) for de novo protein and antibody design, serving pharma partners and an internal pipeline. | Marc Tessier-Lavigne Chairman & CEO Jeff Jonker President and COO Debbie Law Chief Scientific Officer | Licensing Royalties |
| Earendil Labs 🇺🇸 Middletown, DE | AI/ML Biologics Discovery (Antibody Engineering) | Venture-Funded Mar 2026 | Funding $787M | AI-driven biologics discovery platform combining deep learning, generative protein engineering and structural biology to design antibody therapeutics for autoimmune, inflammatory and oncology indications, licensed to pharma partners. | Jian Peng Founder & CEO Zhenping Zhu Co-founder, President & Co-CEO | Licensing Royalties |
| Abridge 🇺🇸 Pittsburgh, PA | AI Clinical Documentation / Ambient Scribing | Series E Jun 2025 | Funding $762M | AI-powered Clinician Intelligence Platform that converts patient-clinician conversations into structured documentation, revenue cycle, nursing, and clinical decision support outputs, embedded in major EHRs and used by 300+ US health systems. | Dr. Shiv Rao CEO and Co-Founder San Oo Chief Technology Officer | Subscription Recurring |
| NewLimit 🇺🇸 South San Francisco, CA | AI/ML-Enabled Biologic Discovery (Epigenetic Reprogramming) | Series C Jun 2026 | Funding $682M | AI-driven epigenetic reprogramming medicines platform (Ambrosia AI, RESTORE-seq) restoring youthful function in old cells, with programs in liver, immune and vascular disease. | Jacob Kimmel Co-founder & CEO Brian Armstrong Co-founder & Board Director | Licensing Royalties |
| Insitro 🇺🇸 South San Francisco, CA | AI/ML Drug Discovery Platform | Series C Mar 2021 | Funding $643M | Full-stack, modality-agnostic AI drug discovery platform combining machine learning, human genetics and high-throughput experimentation, partnered with BMS, Eli Lilly and Gilead. | Daphne Koller CEO and Founder Philip Tagari Chief Scientific Officer | Licensing Royalties |
| Nimbus Therapeutics 🇺🇸 Boston, MA | AI-Enhanced Computational Drug Discovery | Series C | Funding $637M | AI-enhanced computational chemistry platform designing highly selective small-molecule medicines in oncology, immunology and metabolic disease, out-licensed to Big Pharma. | Abbas Kazimi CEO Peter J. Tummino President of R&D | Licensing Royalties Transaction Fee |
| Chai Discovery 🇺🇸 San Francisco, CA | AI Foundation Models for Biomolecular Design | Series C Jul 2026 | Funding $631M | AI foundation models (Chai-1, Chai-2, Chai-3) for biomolecular structure prediction and de novo antibody/miniprotein design, licensed to Eli Lilly and Pfizer. | Joshua Meier Co-founder and CEO Jack Dent Co-founder and President | Licensing Royalties Subscription Recurring |
| LifeMine Therapeutics 🇺🇸 Watertown, MA | AI/ML Platforms for Drug Discovery | Series E Aug 2026 | Funding $563M | Top-Down Drug Discovery platform using AI, machine learning and synthetic biology to mine fungal genomes for genetically encoded small molecules, with lead candidate LIFE-001 in Phase 1 for immune-mediated disorders. | Gregory Verdine Co-Founder, President and CEO Richard Klausner Co-Founder and Chairman | One Time License Licensing Royalties |
| Enveda Biosciences 🇺🇸 Boulder, CO | AI/ML Platforms for Drug Discovery (Natural Products) | Series D Sep 2025 | Funding $530M | AI-driven natural-product drug discovery platform (PRISM foundation model) combining mass spectrometry and a plant-derived molecule library; three clinical-stage assets in inflammation, obesity and IBD. | Viswa Colluru Founder & CEO | Licensing Royalties Subscription Recurring |
| ModMed 🇺🇸 Boca Raton, FL | AI-Native Specialty EHR / Revenue Cycle Automation | Acquired | Funding $486M | Cloud-based, specialty-specific EHR and practice-management platform with AI-native ambient documentation (ModMed Scribe 2.0), automated coding, and revenue-cycle management for ~50,000 US specialty providers. | Daniel Cane Cofounder and Co-CEO Joe Harpaz Founder and Co-CEO | Subscription Recurring Professional Services Transaction Fee |
| Valo Health 🇺🇸 Boston, MA | AI/ML Platforms for Drug Discovery | Series C Oct 2022 | Funding $460M | Opal Computational Platform combining machine learning, causal inference and human data to discover and develop therapeutics in cardiometabolic, oncology and neurodegenerative disease for pharma partners. | Brian M. Alexander CEO David Berry Founder & Former CEO | Licensing Royalties Subscription Recurring |
| Hippocratic AI 🇺🇸 Palo Alto, CA | Healthcare Generative AI Voice Agents | Series C Nov 2025 | Funding $402M | Safety-focused generative AI platform (Polaris Constellation Architecture) delivering voice and chat agents for patient access, nursing, and life-sciences workflows across 1,000+ providers, payors and pharma partners. | Munjal Shah CEO and Co-founder Vishal Parikh Chief Product Officer and Co-founder | Usage Based Subscription Recurring |
| Iambic 🇺🇸 San Diego, CA | AI/ML Platforms for Drug Discovery | Series B Apr 2024 | Funding $397M | AI-driven drug discovery platform (Enchant, NeuralPLexer) integrated with automated wet-lab experimentation to design small-molecule therapeutics for Takeda, Bayer and Jazz Pharmaceuticals. | Tom Miller Co-Founder and CEO Fred Manby Co-Founder and CTO | Licensing Royalties |
| Dewpoint Therapeutics 🇺🇸 Boston, MA | AI/ML Platforms for Drug Discovery | Series D Sep 2025 | Funding $368M | AI-powered ERSA drug discovery platform targeting biomolecular condensate biology to develop condensate-modulating drugs (c-mods) for oncology and neurodegeneration, partnered with Bayer and Novo Nordisk. | Ameet Nathwani CEO | Licensing Royalties |
| Flatiron Health 🇺🇸 New York, NY | Digital & AI-Enabled Diagnostics / Oncology Real-World Evidence | Acquired | Funding $325M | Oncology technology platform combining an ONC-certified EHR (OncoEMR), real-world datasets covering 5M+ cancer patients, and AI-powered analytics (Flatiron Telescope) for biopharma and community oncology practices. | Nathan Hubbard CEO | Subscription Recurring Data Monetisation |
| Ambience Healthcare 🇺🇸 San Francisco, CA | AI Clinical Documentation and Revenue Integrity Software | Series C Jul 2025 | Funding $319M | AI operating system combining ambient listening with chart-aware reasoning to automate clinical documentation, medical coding, and revenue integrity, natively integrated into Epic, Oracle Cerner and athenahealth. | Nikhil Buduma Co-Founder and CEO Mike Ng Co-Founder, President and Chairman | Subscription Recurring Professional Services |
| Arbor Biotechnologies 🇺🇸 Cambridge, MA | AI/ML-Enabled Biologic Discovery (CRISPR Gene Editing) | Series C Mar 2025 | Funding $304M | AI/ML-driven discovery engine mining billions of proteins for a proprietary toolbox of next-generation CRISPR gene editors, licensed to pharma partners including Vertex and Chiesi. | Devyn Smith CEO | Licensing Royalties |
| Genesis Molecular AI 🇺🇸 South San Francisco, CA | AI/ML Platforms for Drug Discovery | Series B Aug 2023 | Funding $296M | GEMS AI operating system for drug discovery, powered by the Pearl foundation model for protein-ligand cofolding, deployed via multi-target collaborations with Incyte and Gilead. | Evan Feinberg CEO and Co-founder | Transaction Fee Licensing Royalties |
| Immunai 🇺🇸 New York, NY | AI/ML-Enabled Biologic Discovery (Immune Mapping) | Series B Oct 2021 | Funding $295M | AI-driven single-cell multiomics platform (AMICA-OS) mapping the human immune system to power target discovery, preclinical evaluation and clinical trial optimization for pharma partners. | Noam Solomon CEO | Subscription Recurring Professional Services |
| Viz.ai 🇺🇸 San Francisco, CA | AI Orchestration & Imaging Analytics (Care Coordination) | Series D Apr 2022 | Funding $292M | Enterprise AI care-coordination platform with 50+ FDA-cleared imaging algorithms deployed across ~2,000 US hospitals for stroke, cardiac, pulmonary and trauma workflows. | Jallel Harrati Chief Revenue Officer | Subscription Recurring Licensing Royalties |
| Iterative Health 🇺🇸 Cambridge, MA | AI-Enabled Diagnostics / Clinical Research Site Network | Series C Apr 2026 | Funding $269M | AI-enabled, community-embedded clinical research site network combining FDA-cleared SKOUT AI polyp detection and AI-ES endoscopic scoring for pharma sponsors and CROs in GI, hepatology, obesity and cardiology. | Jonathan Ng Founder and CEO | Subscription Recurring Licensing Royalties Professional Services |
| Profluent Bio 🇺🇸 Emeryville, CA | AI/ML Platforms for Drug Discovery (Protein Design) | Series B Nov 2025 | Funding $256M | Frontier protein-language foundation models (ProGen3) trained on a 3.4B-sequence protein atlas, coupled to a wet lab, designing AI gene editors, antibodies and enzymes; Eli Lilly deal worth up to $2.25B. | Ali Madani Co-founder and CEO | Licensing Royalties Subscription Recurring One Time License |
| Numerion Labs 🇺🇸 San Francisco, CA | AI/ML Platforms for Drug Discovery | Series D Mar 2026 | Funding $241M | AI superplatform (COSMOS foundation model, APEX enumerator, EXPO optimization) for small-molecule drug discovery in immune and inflammatory disease, run in collaboration with NVIDIA. | Pamela Tsuruda VP, Biology | Licensing Royalties |
| Terray Therapeutics 🇺🇸 Monrovia, CA | AI/ML Platforms for Drug Discovery | Series B Oct 2024 | Funding $225M | AI-native drug discovery platform coupling proprietary wet-lab automation with generative AI models (EMMI, TerraBind) trained on 13B+ target-ligand interactions, partnered with BMS, Gilead and Calico. | Jacob Berlin CEO | Licensing Royalties |
Vertical AI healthcare companies build AI models as the core clinical or scientific product, not as a feature bolted onto existing hospital or pharma software. On this list that splits into four segments: AI drug and biologics discovery (molecule, antibody and gene-editor design), AI clinical documentation and ambient scribing, AI diagnostics and care coordination, and AI-native specialty EHR and revenue-cycle automation.
That distinguishes the category from general digital health, where software digitizes an existing workflow (scheduling, billing, telehealth video) without an AI model doing the clinical or scientific work itself. A company only qualifies here if the AI model is what a partner or provider is actually buying.
The economics split along the same line: the discovery-side companies monetize almost entirely through pharma licensing and royalty deals on drug candidates, while the clinical-workflow companies (documentation, diagnostics, EHR) sell direct subscriptions to hospitals and health systems. Both appear in the revenue model column, and neither dominates the count evenly — discovery outnumbers clinical workflow roughly 2 to 1, per the takeaways above.
Excluded from this list: companies where healthcare is a secondary vertical alongside materials, energy or consumer markets; life-science lab hardware and instrument makers where AI is one feature among many; and real-world-data networks whose core product is a data platform rather than an AI model. The full exclusion list, with reasons, is in the methodology below.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICSIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.